The benefits of postexposure 3'-azido-3'-dideoxythymidine (AZT) prophylaxis following human immunodeficiency virus exposure are unknown. We describe a comprehensive assessment of pre-and postexposure AZT therapy in the feline leukemia virus (FeLV)-cat model for AIDS which included in vitro testing, an in vivo dose-response titration, a postexposure treatment study, plasma drug concentration determinations, and evaluation of the immune response to FeLV. In in vitro studies, AZT prevented FeLV infection of a feline T-lymphoid cell line, giving 50 and 90%o inhibition concentrations of 4.6 and 11.1 nM, respectively. In all of the in vivo efficacy studies, AZT was administered by continuous subcutaneous infusion for 28 days. AZT toxicity was excessive at a dosage of 120 mg/kg of body weight per day, causing acute anemia, but AZT was tolerable at 60 mg/kg/day. In preexposure studies, AZT was efficacious in preventing chronic antigenemia at a dosage of .15 mg/kg/day, at which plasma AZT concentrations averaged between 0.51 and 0.81 ,ug/ml (2.13 and 3.03 pM). 
The antiviral agent 3'-azido-3'-deoxythymidine (AZT) effectively blocks the replication cycle of retroviruses (24) by interfering with the transcription of the viral RNA genome into DNA (36, 37) . AZT does not inhibit virus entry into the cell (32, 37) or affect posttranscriptional processes (2, 34) . Therefore, AZT works prophylactically rather than curatively to prevent the infection of susceptible cells. The double-blind, placebo-controlled trials that led to Food and Drug Administration approval of AZT for the treatment of AIDS demonstrated dramatic reductions in morbidity and a significant increase in life expectancy in patients with AIDS (10) . These Because AZT has the potential to prevent retrovirus infection, it has been used experimentally as an early postexposure chemoprophylactic treatment for primary HIV infections (3) . This form of therapy was originallyjustified on * Corresponding author.
the basis of studies in animal models: feline leukemia virus (FeLV) in cats (34) and murine leukemia virus (MuLV) in mice (31) . The results of the animal studies suggested that pre-or early postexposure AZT therapy effectively prevents retrovirus disease induction. Furthermore, AZT-treated SCID-Hu mice inoculated with HIV have reduced virus loads (23) , and macaques inoculated with simian immunodeficiency virus have delayed virus conversion times (20) or become virus positive but do not succumb to acute disease like untreated control animals do (22) . Subsequent anecdotal reports of early postexposure AZT therapy in humans infected with HIV, however, failed to confirm protection from HIV infection (8, 18, 19) .
It is now apparent that preexposure or early postexposure AZT chemoprophylaxis does not uniformly prevent primary retrovirus infection (1, 8, 18-20, 22, 23, 25, 28, 31, 34) . What may be important in the early stage of infection is the antiviral immune response which controls the spread of infection. In this regard, results of additional work with AZT-treated MuLV-infected mice supported the hypothesis that the high degree of protection observed in that model was due to a drug-induced vaccine effect in which prophylactic AZT therapy suppressed, but did not prevent, early virus expression and thus permitted the equivalent of an attenuated vaccinating infection to proceed (30) .
This report gives a comprehensive evaluation of the efficacy of AZT in pre-and postexposure therapeutic regimens in FeLV-inoculated cats. The drug-mediated protection against FeLV in cats was compatible with the druginduced vaccine effect reported for the MuLV model. Determination of plasma AZT concentrations. Plasma AZT concentrations were determined by high-pressure liquid chromatographic (HPLC) analysis by using a Hewlett-Packard model HP1090 binary pumping system equipped with a diode-array detector. Plasma samples of 200 ,ul collected from individual animals were ifitered through Amicon Cetrifree micropartition ifiters (Amicon Division, W. R. Grace & Co., Danvers, Mass.) to remove plasma proteins. The filtrate was injected onto a Hewlett-Packard Hypersil MDS C8 column (100 by 2.1 mm) with a mobile phase consisting of a mixture of 95% 0.02 M potassium phosphate buffer adjusted to pH 6.0 and 5% acetonitrile. The flow rate was 1 mU/min and the run time was 5.5 min. AZT was detected at 266 nm with peak elution at 3.2 min. External standards were used to prepare a calibration table for concentration determinations. The procedure was sensitive to a concentration of approximately 0.4 p.g/ml.
MATERIALS AND METHODS
Challenge FeLV. The FeLV used as challenge virus was pooled plasma from FeLV-viremic specific-pathogen-free cats experimentally infected with Rickard FeLV. Heparinized blood from seven cats was collected on ice, pooled, and centrifuged. The plasma was distributed into 0.5-ml aliquots and frozen at -85°C until it was used. The pooled plasma contained 4 x 103 focus-forming units per ml, as determined on sarcoma-positive, leukemia-negative 81c cells (11) . The challenge inoculum titrated to induce 100% chronic viremia was 0.1 ml given intravenously. The 50% inhibitory dose was approximately 0.01 ml when the dose was given by the intravenous route.
Pre-and postchaflenge treatment with AZT. AZT was administered by continuous subcutaneous infusion to 8-to 10-week-old cats as described previously (27, 33 (three cats), and after 2 weeks AZT infusion was discontinued (Fig. 2) . Cats given 60 mg/kg/day (seven cats) showed mild regenerative anemia but were able to tolerate the complete 28-day treatment schedule (Fig. 2) . Anemia was not detected in cats (six per group) given dosages of 30 mg/kg/day (Fig. 2) (Fig. 3) . AZT concentrations for the 1-mg/kg/day group were below the detection level and could not be measured. Seven of seven untreated challenge control animals developed chronic antigenemia. FeLV antigen levels in the plasma of cats in which treatment was begun 96 h p.i. were at low or negative levels during the AZT infusion period and throughout the observation period. However, the five of six cats that developed chronic antigenemia after treatment with AZT beginning at 192 h p.i. had low to moderate levels of antigenemia during the AZT infusion period. In these animals, antigenemia rapidly increased to the levels in challenge control animals once AZT was discontinued (Fig. 4) . FeLV gesting that immune sensitization had occurred. In contrast, the antibody responses in the cats given AZT treatments beginning at 24, 48, and 96 h p.i. were apparent beginning at 2 weeks p.i. (Fig. 5) .
DISCUSSION
The risk of seroconversion to HIV per episode of percutaneous exposure to HIV-infected blood is estimated to be approximately 0.4% (3, 15, 21) . Therefore, the benefits of postexposure AZT prophylaxis following virus exposure may not be justified when considering the known short-term toxicity (29) and the unknown long-term effects of AZT therapy (3). The present study was not intended to either support or refute the validity of postexposure chemoprophylaxis for HIV infection. Instead, the study was meant to extend earlier therapeutic studies in the FeLV-cat model by defining more precisely the limits of postexposure therapy in that model and to better characterize the factors that bestow protection against disease. A previous study in FeLVinfected cats used three dosages in two regimens (10 or 20 mg/kg twice daily and 20 mg/kg thrice daily) and three time points for drug initiation (1 h and 7 and 28 days p.i.) (34) . In the present work, a dose titration with five dosages and a postexposure prophylaxis study with five time points after virus exposure were tested; all tests were done by using a uniform regimen. The principal findings were that dosages of >15 mg/kg/day, but not dosages of 1 mg/kg/day, effectively prevent antigenemia. The dosage of 15 mg/kg/day produced mean concentrations of AZT in plasma of 0.57 to 0.81 ,ug/ml (2.13 to 3.03 ,M). Thus, the minimum effective dose was fixed at between 1 and 15 mg/kg/day for continuous subcutaneous infusion. These results were comparable to those in a previous report (34) , in which a dosage of 10 mg/kg/day was reported to prevent viremia. In the in vitro studies in which AZT was added to a feline T-lymphocyte cell line 18 h before virus, the IC90 for inhibition of FeLV antigen expression was 11.1 nM. In a previous study with FeLV, 90% inhibition of infection required approximately 5 ,uM AZT when the drug was added 45 min after virus addition (34) . The requirement in our assay for less AZT for inhibition of >90% virus infection probably related to the preincubation of cells with AZT. The early addition would allow for cellular uptake of AZT and phosphorylation to its active form prior to the addition of virus. In in vivo titration studies, AZT was found to be excessively toxic at a dosage of 120 mg/kg/day, causing acute, severe anemia. Anemia also was evident in the 60-mg/kg/day AZT group, but it remained in a tolerable range during the treatment period and was actually less severe in the last sampling before discontinuance of AZT therapy. Our results were compatible with those of a previous study in which mild anemia was observed in FeLV-infected cats given doses of 30 and 60 mg/kg/day by the oral route in three equal doses at 8-h intervals (14) . In the present study, no toxicity was detected with 30 mg of AZT per kg/day. AZT was administered by continuous infusion, therefore avoiding the peak concentrations in plasma associated with bolus drug administration. The maximum tolerable dosage in cats given AZT by continuous subcutaneous infusion was 60 mg/kg/ day. The improvement in erythrocyte counts at the 4-week treatment sample probably related to the gradual reduction in dosage as body weight increased (the dosage was set at time zero and was not adjusted for weight increases during the 4-week treatment period).
In the postexposure chemoprophylaxis study, AZT therapy (at 60 mg/kg/day) was effective when it was initiated as late as 96 h (4 days) after virus exposure, protecting 20 of 24 animals (83%), but not when it was initiated at 192 h (8 days) p.i., when 5 of 6 animals became chronically antigenemic. The previous report indicated significant protection when AZT was initiated at 7 days p.i. (34) . The discordant results between our study and the previous study may be due to (i) the duration of therapy (28 versus 42 days) or (ii) differences in the rate of spread of the challenge virus. The longer treatment period in the previous study may have permitted additional time for immune clearance to proceed; but the substantial difference in protocols in terms of dosage, method of administration (continuous infusion versus intermittent injection), and duration makes direct comparison difficult. Also, our laboratory-adapted isolate of FeLV may have spread more rapidly in vivo than the isolate reported previously, therefore requiring earlier AZT intervention. The continuous infusion protocol allowed us to quantify the concentrations of AZT in plasma during the treatment period. Such measurements were not reported in the previous study.
The moderate level of antigenemia observed in the 192-h postexposure group during the AZT treatment period (Fig. 4) suggested that AZT inhibits further expansion of infection during the 4-week treatment period. When AZT was discontinued at 28 days of treatment, the level of FeLV antigenemia increased rapidly and achieved levels similar to those in the non-AZT-treated cats (Fig. 4) . While it was not possible to predict how long virus expansion could have been forestalled with continuation of AZT infusion, it was encouraging to see this pattern during the 4-week treatment period.
The pattern of the antiviral antibody response in the postexposure AZT treatment groups indicated primary virus infection, even though, in some animals, no antigenemia was detected. Interestingly, no antibody was detected until after discontinuance of AZT therapy in cats whose AZT therapy began at -48 and 8 h p.i. However, once AZT was discontinued in these two groups, the antibody titers rapidly increased, and by the time that the next plasma sample was obtained (7 days later), it was at a point comparable to that reached at 3 weeks p.i. in FeLV-challenged animals not given AZT therapy (Fig. 5) . The results were compatible with the presence of immune sensitization during AZT therapy, although it was below the level required to give a measurable antibody response. In cats in which AZT therapy was delayed until 24 h p.i. or later, FeLV antibody was detected at week 2 or 3 p.i., a period during which AZT treatment was continuing. These results suggested that when AZT therapy is delayed for 24 h p.i., enough viral antigen accumulates to stimulate antibody production.
The pattern of the immune response noted in our study was compatible with a drug-induced vaccine response previously described by Ruprecht et al. (30) in studies with a Rauscher MuLV-mouse model for AIDS. In the drug-induced vaccine response, drug therapy suppresses but does not eliminate virus expression, allowing enough viral antigen to be processed to prime the immune system. After drug therapy is discontinued, the immune system responds to what presumably would have been a rapid expansion of virus and effectively neutralizes the infection. If drug therapy is delayed too long after exposure, the primary virus infection is able to expand beyond a level which can be controlled by immune factors. In the Rauscher MuLV-mouse system, adoptive cell transfer studies demonstrated that both CD4+ and CD8+ cell types were required for full protection against virus challenge (16) . The relative roles of antibody and/or cellular immunity are not defined for HIV, but some studies indicate that antiviral resistance is probably at least partially mediated by neutralizing antibody (36) . Passive anti-FeLV antibody has been shown to prevent FeLV infection in vivo (7, 12, 17) .
The results presented here suggest that an important aspect of the control of retrovirus infection is inhibition of the very early expansion of infection by suppressing the viremia associated with most primary retrovirus infections. This initial stage of the virus infection process seeds the susceptible cell population at a time when the immune response has not yet fully peaked. In the case of lentiviruses (i.e., HIV [6] , feline immunodeficiency virus [14a] , and simian immunodeficiency virus [20] ), the immune response that follows is able to clear the viremia but at a point that is too late to prevent the widespread dispersion of virus to the susceptible cell population (6) . The immune response to FeLV is different from the general pattern reported for HIV, feline immunodeficiency virus, and simian immunodefi-VOL. 36, 1992 ANTIMICROB. AoENis CHEMOTHER. ciency virus. Like these lentiviruses, FeLV begins with the induction of viremia which is detected by antigen-capture ELISA at about 2 to 3 weeks postexposure. In some cats, however, FeLV, for reasons not fully understood, expands rapidly, causing acute immunosuppression (5, 26) which prevents the resolution of viremia by immune factors. These cats remain viremic for life (13) . Other cats that become immune to FeLV generally have negligible or undetectable levels of viremia (13) and are able to immunologicall limit primary infection and develop what appears to be lifelong immunity to FeLV. The lentiviruses are apparently less immunosuppressive in the early stages of infection, such that infected animals or humans develop strong immune responses to the virus. The immune response clears the viremia and suppresses subsequent virus expression (similar to FeLV-infected cats that develop immunity). However, immunity in these systems is subject to the chronic debilitating effects of T-helper cell depletion that eventually leads to overt immunosuppression and AIDS or AIDS-like diseases. With this difference in pathogenesis taken into consideration, the FeLV system provides a sensitive means of evaluating drug efficacy on the basis of the viremia induction end point. The efficacy of immune prophylaxis for the prevention of HIV infection and AIDS may hinge on preventing the initial stage of viremia and, therefore, limiting the early dissemination of virus. The value of the druginduced vaccine effect in augmenting immunity has not been evaluated.
